Table 1.
Values for sympathetic nerve activity, mean arterial pressure and heart rate at before (i.e. baseline) and after the termination of the protocol (i.e. 60 min after) recording
| SNA (μV) | MAP (mmHg) | HR (beats min–1) | ||||
|---|---|---|---|---|---|---|
| Treatment groups | n | Baseline | Baseline | Post | Baseline | Post |
| Time control | 5 | 3.55 ± 0.36 | 99 ± 6 | 97 ± 6 | 457 ± 18 | 449 ± 17 |
| Losartan control | 4 | 3.44 ± 0.57 | 89 ± 6 | 88 ± 9 | 477 ± 12 | 467 ± 12 |
| AIH + Saline | 5 | 3.34 ± 0.25 | 101 ± 9 | 107 ± 8 | 446 ± 10 | 463 ± 11 |
| AIH + Losartan | 5 | 3.43 ± 0.24 | 88 ± 11 | 90 ± 6 | 439 ± 18 | 437 ± 9 |
| AIH + Aliskiren | 4 | 3.98 ± 0.50 | 98 ± 4 | 95 ± 4 | 431 ± 10 | 427 ± 8 |
| Int.Saline | 4 | 3.21 ± 0.11 | 110 ± 8 | 109 ± 4 | 436 ± 3 | 436 ± 7 |
| Int.Ang II | 5 | 3.18 ± 0.15 | 100 ± 5 | 110 ± 4 | 433 ± 5 | 448 ± 7 |
| Int.Ang II + Losartan | 4 | 3.25 ± 0.46 | 90 ± 5 | 91 ± 7 | 441 ± 16 | 432 ± 11 |
| Single Ang II | 4 | 3.17 ± 0.19 | 102 ± 5 | 105 ± 6 | 414 ± 19 | 414 ± 20 |
| Continuous Ang II | 4 | 3.17 ± 0.18 | 99 ± 8 | 101 ± 5 | 429 ± 7 | 432 ± 11 |
| AIH + Sham | 4 | 3.34 ± 0.40 | 101 ± 8 | 105 ± 6 | 463 ± 8 | 468 ± 11 |
| AIH + CBD | 6 | 3.21 ± 0.34 | 96 ± 4 | 99 ± 5 | 486 ± 7 | 476 ± 10 |
| AIH + SFOvehicle | 4 | 3.49 ± 0.33 | 92 ± 8 | 85 ± 9 | 439 ± 8 | 444 ± 10 |
| AIH + SFOmiss | 4 | 3.19 ± 0.13 | 102 ± 1 | 96 ± 3 | 471 ± 7 | 476 ± 10 |
| AIH + SFOiso | 6 | 3.28 ± 0.25 | 112 ± 5 | 105 ± 7 | 472 ± 5 | 471 ± 8 |
| AIH + CBD∙SFOiso | 6 | 3.71 ± 0.48 | 96 ± 3 | 91 ± 4 | 478 ± 7 | 460 ± 10 |
| Int.Ang II + Sham | 6 | 3.00 ± 0.27 | 104 ± 6 | 106 ± 5 | 450 ± 20 | 449 ± 18 |
| Int.Ang II + CBD | 5 | 3.50 ± 0.27 | 110 ± 3 | 114 ± 4 | 458 ± 10 | 461 ± 11 |
| Int.Ang II + SFOiso | 6 | 4.10 ± 0.35 | 102 ± 4 | 100 ± 5 | 484 ± 10 | 479 ± 11 |
| Int.Ang II + CBD∙SFOiso | 4 | 3.80 ± 0.54 | 91 ± 6 | 92 ± 5 | 464 ± 9 | 468 ± 13 |
| Int.Phenylephrine | 5 | 3.32 ± 0.41 | 101 ± 8 | 101 ± 13 | 426 ± 8 | 427 ± 3 |
| Int.Phenylephrine + Aliskiren | 4 | 3.10 ± 0.17 | 108 ± 6 | 112 ± 6 | 431 ± 6 | 428 ± 4 |
| Continuous phenylephrine | 4 | 3.21 ± 0.13 | 103 ± 7 | 102 ± 8 | 410 ± 3 | 407 ± 6 |
| Int.Sodium nitroprusside | 6 | 3.31 ± 0.26 | 115 ± 6 | 115 ± 7 | 433 ± 5 | 432 ± 8 |
Values are in mean ± SEM. One‐way ANOVA with Holm–Šidák correction was used for multiple comparisons between groups for baseline SNA, MAP and HR values. Two‐way ANOVA with Holm–Šidák correction was used for multiple comparisons between baseline and post‐protocol values for MAP and HR values. There were no differences between all comparisons.